Media ReleasesBionomics Limited

View All Bionomics Limited News

Bionomics Limited (ASX: BNO) BNC105 Renal Cancer Trial Update

- Dosing in renal cancer trial clears 16mg/m² dose level
- Combination of Afinitor and BNC105 safe and well tolerated
- BNC105 is the first tumour blood vessel inhibitor to combine well with Afinitor
- BNC105 has the potential to represent an entirely new treatment paradigm for patients with renal cancer
- Over 100,000 people die of renal cancer in the world each year; it is the 7th most common form of cancer
- On track to open 21 clinical trial sites across the US by the end of

For further information please download this document.

Download this document